公开(公告)号：US20230150963A1

公开(公告)日：2023-05-18

申请号：US18077966

申请日：2022-12-08

申请人： Tactogen Inc.

发明人： Matthew Baggott

IPC分类号： C07D307/81 ,  A61P25/18 ,  A61P25/24

CPC分类号： C07D307/81 ,  A61P25/18 ,  A61P25/24

摘要： Pharmaceutically active benzofuran compositions for the treatment of mental disorders or for mental enhancement, including for entactogenic therapy. The present invention also includes benzofuran compounds, compositions, and methods for generally modulating central nervous system activity and treating central nervous system disorders.

公开(公告)号：US20240308999A1

公开(公告)日：2024-09-19

申请号：US18653750

申请日：2024-05-02

申请人： TACTOGEN INC

发明人： Matthew J. Baggott

IPC分类号： C07D471/04 ,  A61K31/437 ,  A61P25/22

CPC分类号： C07D471/04 ,  A61K31/437 ,  A61P25/22

摘要： The present invention discloses a compound, composition, method for modulating central nervous system activity, or method for treating central nervous system disorders, such as post-traumatic stress and adjustment disorders, comprising an indolizine-containing compound having a structure disclosed herein.

公开(公告)号：US11767305B2

公开(公告)日：2023-09-26

申请号：US18077966

申请日：2022-12-08

申请人： Tactogen Inc

发明人： Matthew Baggott

IPC分类号： C07D307/81 ,  A61P25/18 ,  A61P25/24

CPC分类号： C07D307/81 ,  A61P25/18 ,  A61P25/24

摘要： Pharmaceutically active benzofuran compositions for the treatment of mental disorders or for mental enhancement, including for entactogenic therapy. The present invention also includes benzofuran compounds, compositions, and methods for generally modulating central nervous system activity and treating central nervous system disorders.

公开(公告)号：US20230257347A1

公开(公告)日：2023-08-17

申请号：US18123812

申请日：2023-03-20

申请人： Tactogen Inc

发明人： Matthew Baggott

IPC分类号： C07D209/16

CPC分类号： C07D209/16 ,  C07B2200/07

摘要： Pharmaceutically active advantageous tryptamine compounds and their pharmaceutically acceptable salts, salt mixtures and pharmaceutically acceptable compositions are disclosed for the treatment of mental disorders or for mental enhancement, including for entactogenic therapy, and generally for modulating central nervous system activity.

公开(公告)号：US20240335414A1

公开(公告)日：2024-10-10

申请号：US18737589

申请日：2024-06-07

申请人： TACTOGEN INC

发明人： Matthew J. Baggott ,  Sean Dalziel

IPC分类号： A61K31/343 ,  A61K9/20 ,  A61K31/137

CPC分类号： A61K31/343 ,  A61K9/2054 ,  A61K9/2086 ,  A61K9/2095 ,  A61K31/137

摘要： The present invention discloses specialized combinations and methods of use thereof that may be used for beneficially modulating the central nervous system and for treating central nervous system, inflammatory, and metabolic disorders.

公开(公告)号：US20240083864A1

公开(公告)日：2024-03-14

申请号：US18371935

申请日：2023-09-22

申请人： Tactogen Inc

发明人： Matthew Baggott

IPC分类号： C07D307/81 ,  A61P25/22 ,  A61P25/24

CPC分类号： C07D307/81 ,  A61P25/22 ,  A61P25/24

摘要： Pharmaceutically active benzofuran compositions for the treatment of mental disorders or for mental enhancement, including for entactogenic therapy. The present invention also includes benzofuran compounds, compositions, and methods for generally modulating central nervous system activity and treating central nervous system disorders.

公开(公告)号：US20230183199A1

公开(公告)日：2023-06-15

申请号：US18106273

申请日：2023-02-06

申请人： Tactogen Inc.

发明人： Matthew Baggott

IPC分类号： C07D307/79

CPC分类号： C07D307/79

摘要： The present invention discloses 2-aminoindane Formulas I and II and their pharmaceutically acceptable salts, compositions and methods of use to modulate central nervous system activity, and to treat central nervous system disorders, such as post-traumatic stress, depression, anxiety, and adjustment disorders. In certain embodiments, the compounds of the present invention can be used for entactogenic therapy in counseling sessions, as needed periodically or consistently as necessary or desired.

公开(公告)号：US20230159487A1

公开(公告)日：2023-05-25

申请号：US18093773

申请日：2023-01-05

申请人： TACTOGEN INC

发明人： Matthew Baggott

IPC分类号： C07D333/58 ,  C07D333/56 ,  A61P25/22

CPC分类号： C07D333/58 ,  C07D333/56 ,  A61P25/22

摘要： Pharmaceutically active benzothiophene compounds and their pharmaceutically acceptable salts and salt mixtures and pharmaceutically acceptable compositions for the treatment of mental disorders or for mental enhancement, including for entactogenic therapy, and generally for modulating central nervous system activity.